クラドリビンは,慢性進行性多発性硬化症の治療に用いられる
J C Sipe1, J S Romine, J A Koziol
1Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
Lancet (London, England)
|July 2, 1994
まとめ
免疫抑制薬クラドリビンは,神経学的スコアを安定させ,脱ミエリン化を軽減することにより,慢性進行性多発性硬化症 (MS) に好ましい影響を及ぼしました. この研究では,クラドリビンがMS患者にとって安全で効果的な治療法であることが判明しました.
科学分野:
- 神経免疫学 神経免疫学とは
- 臨床薬理学 臨床薬理学とは
背景:
- 多発性硬化症 (MS) は,慢性的で進行性であり,障害となる脱ミエリン症候群である.
- 自己免疫プロセスは,MSの病原性において重要な役割を果たすと考えられています.
研究 の 目的:
- 慢性進行性多発性硬化症の患者における核酸薬クラドリビンの有効性と安全性を評価する.
- クラドリビンの神経学的状態,脱ミエリネーション,脳脊髄液マーカーに対する影響を評価する.
主な方法:
- ランダム化され,ダブルブラインド試験で,慢性進行性MSの51人の患者が参加しました.
- 患者は,中央線経由で投与されたクラドリビン (0.7 mg/kg) またはプラセボのいずれかの4ヶ月のコースを受けた.
- 神経学的評価,脳脊髄液分析,脳MRIは12ヶ月間にわたって定期的に行われました.
主要な成果:
- クラドリビンで治療された患者は,プラセボ群と比較して,MRIで神経学的スコアが安定または改善し,デミエリン化体積が減少した.
- 脳脊髄液のオリゴクローナル帯の濃度は,クラドリビン群でも安定または改善した.
- クラドリビンは一般的によく耐えられ,有意な毒性 (髄膜抑制) の症例は1件のみでした.
結論:
- 免疫抑制薬クラドリビンは,慢性進行性多発性硬化症の経過に好意的に影響を与えます.
- クラドリビンは,疾患の進行を安定させることに有効性を示しており,一般的によく耐えます.
さらに関連する動画
関連する概念動画
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...